Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected patients by synthesizing several inflammatory medi...
Guardado en:
Autores principales: | Cutolo M, Meroni M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5d3a696edf404f14beeee91665f68c15 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington R, et al.
Publicado: (2020) -
The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis
por: Binymin K, et al.
Publicado: (2011) -
Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
por: Zhang N, et al.
Publicado: (2021) -
Synergistic induction of CX3CL1 by TNF alpha and IFN gamma in osteoblasts from rheumatoid arthritis: involvement of NF-kappa B and STAT-1 signaling pathways
por: Kuninobu Wakabayashi, et al.
Publicado: (2008) -
Translational utility of experimental autoimmune encephalomyelitis: recent developments
por: Guerreiro-Cacais AO, et al.
Publicado: (2015)